The cellular pathology market size is expected to grow from USD 11.70 billion in 2025 to USD 12.74 billion in 2026 and is forecast to reach USD 19.54 billion by 2031 at 8.92% CAGR over 2026-2031. This report is Segmented by Product and Service (Instruments, Consumables, and More), by Technology (Histopathology, Cytopathology, and More), by Application (Clinical Diagnostics and More), by Indication (Oncology, Infectious Diseases, and More), by End User (Hospitals and Health Systems, and More), and Geography (North America, and More). The Market Forecasts are Provided in Terms of Value (USD).
FDA clearances have helped laboratories consider scanner purchases for primary diagnostic use. Roche's VENTANA DP 200 and DP 600, Epredia's E1000 Dx, Indica Labs' HALO AP Dx, and OptraSCAN's OS-Ultra were among systems cleared between December 2024 and July 2026. Software and image-management systems grow as scanners are deployed. Service contracts and remote reporting arrangements also add recurring revenue. ISO 15189 accreditation requirements reinforce the value placed on laboratory-quality consumables. The cellular pathology market continues to rely on consumables for volume while equipment renewal supports the next phase of growth.
Histopathology held 42.95% of the technology-segment revenue in 2025. H&E staining and morphological review remain the standard first-line assessment for tissue-based cancer diagnosis. Immunohistochemistry remains important where treatment requires a companion diagnostic. Agilent's PD-L1 IHC 28-8 pharmDx had 8 FDA-approved indications by July 2026. Digital pathology is forecast to advance at a CAGR of 10.54% through 2031. This gives digital systems the strongest growth rate among technology categories.
Molecular pathology and AI-enabled pathology are also gaining relevance as testing becomes more biomarker-focused. Natera reported 54% year-over-year growth in oncology test volumes in the first quarter of 2026. Signatera CDx became the first FDA-approved companion diagnostic for molecular residual disease testing in oncology. Cytopathology, flow cytometry, and in situ hybridization retain specialized roles in hematological, reproductive, and other targeted workflows. Their clinical role remains important where alternative approaches are limited. Digital systems add new ways to manage and interpret cases without replacing the core value of tissue morphology. The cellular pathology market benefits when these technologies are used together in a single diagnostic pathway.
Europe is the second-largest regional contributor to the cellular pathology market. Germany combines precision oncology demand with an established in vitro diagnostics manufacturing base. The United Kingdom, France, Italy, and Spain account for much of the region's testing volume. NHS England's pathology consolidation program supports hub-and-spoke digital networks. The EU In Vitro Diagnostic Regulation affects validation and post-market obligations for companion diagnostics and digital pathology systems. These obligations favor vendors with established regulatory capabilities.
Asia-Pacific is forecast to grow at a CAGR of 10.72% through 2031. Asia represented more than 50.7% of global cancer cases in 2024. China and India are expanding laboratory infrastructure and cancer screening capacity. Japan's pathology guidance supports the use of digital pathology images in diagnostic practice. South Korea and Australia remain advanced markets, while Indian laboratory development is extending into tier-2 and tier-3 cities. The markets in Middle East and Africa and South America are smaller, but PathAI's collaboration with A.C.Camargo Cancer Center in Brazil shows the growing interest in AI-enabled pathology in these regions.
Global Cellular Pathology Market Trends and Insights
Rising Cancer and Chronic-Disease Diagnostic Workloads
Cancer incidence continues to create demand for histological and cytological examinations across the cellular pathology market. IARC recorded 20.6 million new cancer diagnoses in 2024, and lung, female breast, and colorectal cancers were the largest incidence categories. Annual cancer incidence is projected to reach 35 million cases by 2050. Tissue assessment also supports diagnosis for rheumatoid arthritis, autoimmune hepatitis, primary biliary cholangitis, and IgG4-related disease. Higher screening coverage for these conditions can add slide volumes in histology and immunohistochemistry laboratories. National prevention programs that incorporate early detection can make pathology capacity a lasting part of public-health delivery.Precision Oncology and Companion-Diagnostic Adoption
Companion diagnostics create recurring testing needs because treatment protocols specify a validated assay before therapy begins. In July 2026, Agilent received FDA approval for PD-L1 IHC 28-8 pharmDx with OPDIVO for esophageal squamous cell carcinoma, gastric, gastroesophageal junction, and esophageal adenocarcinoma indications. This was the 8th FDA-approved indication for the platform. FoundationOne CDx also gained FDA approvals in 2026 for Itovebi and TEPMETKO. These approvals place tissue-based biomarker evaluation further into cancer treatment pathways. The cellular pathology market therefore gains demand that is linked to treatment decisions rather than discretionary laboratory spending.High Capital and Total-Cost-of-Ownership Requirements
Digital workflows require scanners, software licenses, information technology infrastructure, image storage, and maintenance support. High-throughput scanners can process more than 300 slides per hour, but their installation also requires laboratory information system validation, network upgrades, and calibrated displays. Hospitals assess these needs as a total cost of ownership rather than as a single equipment purchase. Lower reimbursement levels can make the initial investment difficult for hospitals in Sub-Saharan Africa and parts of South America. Early adopters also carry transition costs before higher digital volumes improve cost-per-case economics. These conditions can preserve conventional microscopy in mid-sized hospital networks.Other drivers and restraints analyzed in the detailed report include:
- Digital Pathology, AI, and Telepathology Adoption
- AI-Ready Cellular Pathology Data Generation from Routine Slides
- Pathologist and Histotechnologist Shortages
Segment Analysis
Consumables held 61.23% of segment revenue in 2025. Reagents, antibodies, and diagnostic kits are used repeatedly in clinical and research workflows. Immunohistochemistry protocols often require specific validated antibody clones. This supports the use of branded consumables and limits substitution with unvalidated products. Instruments are projected to record a CAGR of 9.87% through 2031. The cellular pathology market size for instruments is supported by laboratories replacing conventional platforms with digital-ready systems.FDA clearances have helped laboratories consider scanner purchases for primary diagnostic use. Roche's VENTANA DP 200 and DP 600, Epredia's E1000 Dx, Indica Labs' HALO AP Dx, and OptraSCAN's OS-Ultra were among systems cleared between December 2024 and July 2026. Software and image-management systems grow as scanners are deployed. Service contracts and remote reporting arrangements also add recurring revenue. ISO 15189 accreditation requirements reinforce the value placed on laboratory-quality consumables. The cellular pathology market continues to rely on consumables for volume while equipment renewal supports the next phase of growth.
Histopathology held 42.95% of the technology-segment revenue in 2025. H&E staining and morphological review remain the standard first-line assessment for tissue-based cancer diagnosis. Immunohistochemistry remains important where treatment requires a companion diagnostic. Agilent's PD-L1 IHC 28-8 pharmDx had 8 FDA-approved indications by July 2026. Digital pathology is forecast to advance at a CAGR of 10.54% through 2031. This gives digital systems the strongest growth rate among technology categories.
Molecular pathology and AI-enabled pathology are also gaining relevance as testing becomes more biomarker-focused. Natera reported 54% year-over-year growth in oncology test volumes in the first quarter of 2026. Signatera CDx became the first FDA-approved companion diagnostic for molecular residual disease testing in oncology. Cytopathology, flow cytometry, and in situ hybridization retain specialized roles in hematological, reproductive, and other targeted workflows. Their clinical role remains important where alternative approaches are limited. Digital systems add new ways to manage and interpret cases without replacing the core value of tissue morphology. The cellular pathology market benefits when these technologies are used together in a single diagnostic pathway.
Complete Report Scope:
- By Product and Service
- Instruments
- Microtomes and Cryostats
- Tissue Processors
- Automatic Stainers
- Whole-Slide Imaging Scanners
- Pathology Workstations and Displays
- Consumables
- Diagnostic Kits
- Reagents and Antibodies
- Probes and Molecular Kits
- Software and Image-Management Systems
- Services
- Instruments
- By Technology
- Histopathology
- Cytopathology
- Immunohistochemistry
- In Situ Hybridization
- Digital Pathology
- Molecular Pathology
- Flow Cytometry
- AI-Enabled Pathology
- By Application
- Clinical Diagnostics
- Genetic and Molecular Testing
- Drug Discovery and Development
- Toxicology and Safety Assessment
- Research, Education and Training
- By Indication
- Oncology
- Infectious Diseases
- Inflammatory and Autoimmune Disorders
- Gastrointestinal Diseases
- Neurological Diseases
- Gynecological Diseases
- Others
- By End User
- Hospitals and Health Systems
- Diagnostic and Reference Laboratories
- Research Laboratories and Academic Centers
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Specialty Clinics and Cancer Centers
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America held 41.67% of global revenue in 2025. The region benefits from extensive use of tissue-based companion diagnostics, established reimbursement for immunohistochemistry and molecular pathology, and academic medical centers that are adopting digital platforms. The United States has received several FDA clearances for whole-slide imaging systems since December 2024. Quest Diagnostics expanded oncology test access through OncoEMR Molecular Profiling Integration in July 2026. The service supports 4,700 clinicians across 1,600 community cancer locations. Canada and Mexico provide smaller but growing contributions through cancer-care investment and private laboratory expansion.Europe is the second-largest regional contributor to the cellular pathology market. Germany combines precision oncology demand with an established in vitro diagnostics manufacturing base. The United Kingdom, France, Italy, and Spain account for much of the region's testing volume. NHS England's pathology consolidation program supports hub-and-spoke digital networks. The EU In Vitro Diagnostic Regulation affects validation and post-market obligations for companion diagnostics and digital pathology systems. These obligations favor vendors with established regulatory capabilities.
Asia-Pacific is forecast to grow at a CAGR of 10.72% through 2031. Asia represented more than 50.7% of global cancer cases in 2024. China and India are expanding laboratory infrastructure and cancer screening capacity. Japan's pathology guidance supports the use of digital pathology images in diagnostic practice. South Korea and Australia remain advanced markets, while Indian laboratory development is extending into tier-2 and tier-3 cities. The markets in Middle East and Africa and South America are smaller, but PathAI's collaboration with A.C.Camargo Cancer Center in Brazil shows the growing interest in AI-enabled pathology in these regions.
List of Companies Covered in this Report:
- Abbott Laboratories
- Agilent Technologies
- Aiforia Technologies Plc
- Beckton Dickinson
- BioGenex
- Danaher
- Roche
- FUJIFILM
- Hamamatsu Photonics
- Hologic
- Indica Labs, LLC
- Koninklijke Philips
- NeoGenomics Laboratories
- OptraSCAN
- PathAI, Inc.
- PHC Holdings
- Proscia
- Sakura Finetek
- Sysmex
- Thermo Fisher Scientific
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Agilent Technologies, Inc.
- Aiforia Technologies Plc
- Becton, Dickinson and Company
- BioGenex
- Danaher Corporation
- F. Hoffmann-La Roche Ltd.
- Fujifilm Holdings Corporation
- Hamamatsu Photonics K.K.
- Hologic, Inc.
- Indica Labs, LLC
- Koninklijke Philips N.V.
- NeoGenomics Laboratories, Inc.
- OptraSCAN
- PathAI, Inc.
- PHC Holdings Corporation
- Proscia Inc.
- Sakura Finetek USA, Inc.
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
